Evidence map›Paper›PMID 41125904›Full record

ArticleCancer gene therapy2026

SATB1 regulates TXNIP inhibiting invasion and infiltration in T-cell acute lymphoblastic leukemia.

Lang He, Huo Tan, Anqiao Li, Runhui Zheng, Danyun Yuan, Yimin Chen, Shuyi Chen, Jiaoyuan Qin, Li Tan, Sida Peng and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lang He *Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Huo Tan *Department of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Anqiao Li *Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Runhui ZhengDepartment of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Danyun YuanDepartment of Hematology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yimin ChenDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shuyi ChenDepartment of Hematology, First People's Hospital of Foshan, Foshan, China.
Jiaoyuan QinDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Li TanDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Sida PengDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhenqian HuangDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. huangzq2013@163.com.
Lihua XuDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. xlhua@gzhmu.edu.cn.ORCID 0000-0002-3437-1286

Funding

Guangzhou Science and Technology Program key projects 2023A03J0347Guangzhou Science and Technology Program key projects 2023A03J0348Guangzhou Science and Technology Program key projects 2024A03J1149
6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a poor prognosis. Thioredoxin-interacting protein (TXNIP), a key protein, binds to thioredoxin and acts as a tumor suppressor in multiple cancers. However, its specific functions and mechanisms in T-ALL remain unclear. Here, CCK-8 and Transwell assays were used to assess its proliferation and invasiveness, with findings validated in a murine leukemia model. 4D proteomics combined with bioinformatics analyses were applied to elucidate its role in DNA damage repair. Guided by CHIP-seq results, we further validated the regulatory axis between Special AT-rich sequence binding protein 1 (SATB1) and TXNIP, as well as their involvement in T-ALL invasion, using CHIP-PCR and rescue assays. Our data demonstrated low expression of TXNIP in T-ALL patients. TXNIP significantly inhibited the proliferation and invasiveness of T-ALL cells and was involved in DNA damage response by suppressing MRN complex (MRE11-RAD50-NBS1) expression. We also identified SATB1 as a transcriptional regulator of TXNIP in Jurkat cells. Notably, TXNIP overexpression counteracted the pro-invasive effects induced by SATB1 knockdown in Jurkat cells (P < 0.05). In summary, TXNIP inhibits the proliferation and invasion of T-ALL, and impairs DNA damage repair processes. SATB1 positively regulates TXNIP, thereby suppressing the invasiveness of Jurkat cells.

Indexed as

Carrier ProteinsLeukemic InfiltrationMatrix Attachment Region Binding ProteinsNeoplasm InvasivenessPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalHumansMiceThioredoxinsCarrier ProteinsMatrix Attachment Region Binding ProteinsSATB1 protein, humanSatb1 protein, mouseThioredoxinsTXNIP protein, humanTxnip protein, mouse

Identifiers

PMID41125904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.